LTR Pharma (ASX:LTP) Other Long-Term Liabilities: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:LTP LTR Pharma Ltd ASX:LTP
7 GF Score
Price A$0.46
View Full Analysis

What is LTR Pharma Other Long-Term Liabilities?

LTR Pharma ASX:LTP -7.14% 7 Other Long-Term Liabilities is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 7/100.

LTR Pharma's other long-term liabilities for the quarter that ended in Dec. 2025 was A$0.00 Mil.

LTR Pharma Other Long-Term Liabilities Related Terms

LTR Pharma Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Other Long-Term Liabilities Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
0.00 0.00 0.00 0.00 0.00

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ASX:LTP
7GF Score
LTR Pharma Ltd ASX:LTP
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.00 Mil mean?
LTR Pharma (ASX:LTP) has a Other Long-Term Liabilities of A$0.00 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Other Long-Term Liabilities too high?
LTR Pharma's current Other Long-Term Liabilities is A$0.00 Mil. Overall, LTR Pharma has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Other Long-Term Liabilities compare to VRTX and REGN?
LTR Pharma's Other Long-Term Liabilities of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on LTR Pharma and its competitors. LTR Pharma's current Other Long-Term Liabilities is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Other Long-Term Liabilities of A$0.00 Mil. The current Other Long-Term Liabilities is A$0.00 Mil. LTR Pharma's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Other Long-Term Liabilities is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
7GF Score

Get the complete analysis for ASX:LTP

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.46
Price